Chemical ID: CAS Formula HS Code Database – Metronidazole

Section	Details
Product Name & IUPAC Name	Product Name: Metronidazole IUPAC Name: 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethanol
Chemical Formula	C6H9N3O3
Synonyms & Trade Names	Synonyms and trade names follow regional and application preferences. Commonly observed alternatives include 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole and Flagyl (trade). Product release to downstream supply chains, especially in pharmaceutical solid dosage manufacture, often references regional pharmacopoeia-aligned synonyms. Naming requirements for regulatory, import, or labeling purposes typically align with finished drug registration or raw material supply contracts.
HS Code & Customs Classification	Global customs classification usually assigns HS Code 29332900 for metronidazole, grouped under "heterocyclic compounds with nitrogen hetero-atom(s) only; other." Code assignment can vary in specific trade zones due to updates in regulatory harmonization or sub-code selection for pharmaceutical actives.

Manufacturer’s Perspective on Identification and Classification

Chemical identification for a production batch starts with an in-process review of structural integrity (NMR/IR, mass spec confirmation as demanded by release standards). Nomenclature applied on QC/QA documentation follows both IUPAC and major pharmacopeial naming conventions, which avoids confusion in cross-border shipment and downstream processing.

Synonym selection, especially for trade channel or national compendia, reflects the end-use: generic pharmaceutical manufacturing relies on harmonized INN or USP/EP compendial naming for audit trails, while raw chemical supply in non-pharma industries often applies the simplest structure-based synonym. Errors in classification on inbound raw material can arise from reliance on out-of-date customs coding; internal compliance teams routinely reconcile customs codes with current WCO guidelines and buyer-specific import criteria.

Customs entry and export require confirmation of CAS number with the assigned HS code. Production documentation must align regulatory paperwork with on-batch analyses so that regulatory inspections and audits track the product identity all the way from raw material selection through to warehouse release and shipment.

Choices made in chemical identification at the plant level influence downstream acceptance test protocols, pharmacopoeia compliance, global sales contracts, and risk of customs clearance delays. Technical departments monitor regulatory changes to HS codes so exported product avoids port-of-entry complications due to mismatches between batch documentation and customs records.

Metronidazole: Technical Properties, Manufacturing Process & Safety Guidelines

Physical & Chemical Properties

Physical State & Appearance

Metronidazole is commonly isolated as a crystalline solid. The form, color, and particle size can vary based on crystallization solvent, agglomeration control, and milling protocol. Technical grade may be off-white or pale yellow, while pharmaceutical grades require tighter appearance and odor controls. Odor is generally faint or absent if adequately purified.

Melting point varies with polymorphic form, process impurities, and moisture content—critical attributes for downstream formulation. Manufacturers monitoring these properties during batch release minimize batch-to-batch performance deviation.

Chemical Stability & Reactivity

Under typical production and storage conditions, metronidazole remains stable. Process streams containing oxidants, acids, or metals introduce risk of nitro group reduction or hydrolytic decomposition. Process validation confirms compatibility of equipment materials, intermediates, and utilities with bulk active.

Solubility & Solution Preparation

Solubility in water and polar organic solvents varies by grade and residual solvent profile. Full dissolution typically requires finely milled product, control of pH, and avoidance of incompatible excipients. Residual moisture, solvent cut selection, and milling parameters influence reconstitution behavior—a major concern for injectable and suspension grades.

Technical Specifications & Quality Parameters

Specification Table by Grade

Detailed specifications and release parameters are established for each grade and use case. These cover assay (content by HPLC or titration), identification, related substances, heavy metal content, residual solvents, polymorph profile, and moisture.

Parameter	Standard Grade	Pharmaceutical Grade
Assay	Typical values depend on grade	Defined by pharmacopeial or customer criteria
Polymorph	Not always specified	Strictly controlled for certain formulations
Odor/Color	May show minor variation	Tight limits, monitored batch-wise
Impurities	Profiled by internal standards	Controlled by recognized pharmacopeial monograph or client specification

Impurity Profile & Limits

Main impurities arise from raw material quality, incomplete reaction, and process byproducts. Major contributors include related nitroimidazole compounds, desmethyl analogs, and residual solvents. Each manufacturing site establishes and routinely reviews internal impurity trends. Critical limits are set according to regional regulations, customer-driven thresholds, and reference monographs. Out-of-trend excursions trigger root-cause investigation and corrective actions.

Test Methods & Standards

Manufacturing labs use validated analytical methods—typically HPLC and GC—for content, identity, and impurity testing. Methods align to pharmacopeias (USP, EP) where needed, with in-house methods optimized for process control. Test parameters are defined batch-wise for every production run, with retained samples tested against customer-required and registration-driven release standards.

Preparation Methods & Manufacturing Process

Raw Materials & Sourcing

The principal starting materials for metronidazole synthesis include chlorinated ethanols and nitroimidazole intermediates. Reagent selection depends on process route, availability, and impurity burden. Supplier qualification programs focus on traceability, batch consistency, and contaminant profile, especially for pharmaceutical use.

Synthesis Route & Reaction Mechanism

The traditional manufacturing route is the alkylation of 2-methyl-5-nitroimidazole with 2-chloroethanol under basic or neutral conditions. Process selection reflects access to reagents, safety controls, and environmental compliance. Side reactions depend on reagent excess, byproduct management, and mixing protocol.

Process Control & Purification

Precise temperature, pH, and reaction time control are critical. Process analytical technology enables real-time monitoring of endpoint and byproduct content. Intermediate purification (extraction, crystallization, filtration) reduces impurity carryover. Manufacturers optimize solvent selection for minimal residue and high product yield. Final purification may entail multiple crystallizations or activated carbon treatment according to downstream grade requirement.

Quality Control & Batch Release

Batch records include stepwise monitoring, deviation tracking, and analytical test results. Only batches passing internal and customer-defined tests are released. Stability samples are retained and periodically tested for all pharmaceutical shipments.

Chemical Reactions & Modification Potential

Typical Reactions

Metronidazole can undergo nitro group reduction, alkylation, or acylation under controlled laboratory conditions. Reaction kinetics and selectivity depend on catalyst, temperature, and solvent—relevant for process optimization or route scouting.

Reaction Conditions

Reductive transformations often employ hydrogenation or transfer hydrogenation with tailored metal catalysts at controlled pressure and temperature. Solvent and base choice significantly alters regioselectivity and impurity formation.

Derivatives & Downstream Products

Chemical modification enables production of prodrugs or derivatives for research and specialty use. Regulatory compliance and quality management guide scale-up if conversion of metronidazole into formulated products or intermediates is performed on site.

Storage & Shelf Life

Storage Conditions

Bulk solid metronidazole requires storage at controlled room temperature with protection from excessive heat and humidity. Exposure to light accelerates discoloration and potential impurity growth, especially in open or permeable containers.

Manufacturers prefer inert or lined containers for bulk storage, particularly for export shipments. Packs must be fully sealed and labeled with traceable batch identifiers.

Container Compatibility, Shelf Life & Degradation Signs

Compatibility testing confirms no extractables or leachables from high-density polyethylene, glass, or composite drums under standard holding conditions. Signs of degradation include darkening, odor development, and loss of crystallinity—these trigger internal non-conformance protocols. Typical shelf life claims follow regulatory or client requirements based on stability data.

Safety & Toxicity Profile

GHS Classification, Hazard & Precautionary Statements

Metronidazole holds hazardous chemical assignments according to regional regulations. Its GHS classification considers acute toxicity, chronic health effects, and possible environmental impact. Clear labeling with hazard pictograms, risk phrases, and handling instructions is applied at all packaging stages.

Toxicity Data, Exposure Limits & Handling

Toxicological data are based on active ingredient exposure in manufacturing settings, handling concentrated dust, and accidental skin contact or inhalation. Exposure control relies on contained systems, use of local exhaust, and operator PPE as defined in site-specific risk assessments. Occupational limits are observed, with regular health monitoring of production staff. Spills or uncontrolled releases are managed using predefined plant incident protocols, with strict tracking and remediation.

Metronidazole Supply Capacity, Commercial Terms & 2026 Price Trend Forecast

Supply Capacity & Commercial Terms

Production Capacity & Availability

Production of metronidazole varies according to plant design, access to key precursors, and operating days per year. For bulk orders, availability—especially beyond 10 metric tons per lot—will fluctuate by season, plant maintenance cycles, and regional raw material supply. Production shutdowns due to environmental audits remain a factor in China, shifting global supply for months out of the year. Commercially, actual availability will always track both scheduled outputs and unexpected downtime or compliance-driven reductions.

Lead Time & MOQ

Minimum order quantities are often dictated by both production batch size and packaging format selected by the customer. Standard MOQ for export usually lands at one full pallet or drum (typical industrial scale), but can shift upward in periods of feedstock volatility. Lead time for regular orders, under stable conditions, ranges from 2 to 5 weeks; expedited processing is subject to capacity and depends on backlogs related to larger institutional tenders.

Packaging Options

Bulk metronidazole, technical and pharmaceutical grades, typically ship in fiber drums or HDPE containers with internal double PE liners. Aseptic packaging can be provided for pharma applications, always requiring additional QC finished product testing. Bag-in-box systems, 25kg units, and smaller bottles for research are available for specific customer protocols. Weight tolerances and packaging sterility requirements are outlined at the contract review stage, as are labeling customs for regulated markets.

Shipping & Payment Terms

Direct shipment is normally FCA or FOB main export ports for international business, though CFR, CIF, or DAP is also possible depending on destination and negotiation. Full regulatory documentation accompanies each shipment. Payment terms move with the buyer’s trading history. L/C at sight is default for first-time orders, while net 30 or 60 may apply for repeat partners. Advance deposit conditions can be tightened during demand surges or raw material shocks.

Pricing Structure & Influencing Factors

Raw Material Cost Composition

Raw material cost for metronidazole revolves around nitroimidazole feedstock pricing, sulfuric acid, and catalyst inputs. Volatility here is driven by regional production restraints, energy price swings, and changes in environmental levies (especially East Asia). Feedstock grades set by supplier specification directly impact impurity profile, yield, and downstream purification expense. Higher purity base costs more due to upstream process intensification and added analysis, particularly for injectable API grades. Compliance with GMP and local regulatory requirements, such as US DMF or CEP, further increases release QC and batch documentation costs.

Fluctuation Causes

Feedstock price inconsistencies stem from both petroleum-linked commodity cycles and geo-political upsets affecting precursors. Regulatory action (shutdown of polluting units, restrictions on hazardous by-product handling) routinely cuts available capacity, pushing spot prices higher. Costs also fluctuate on sudden currency shifts, worker strikes, and logistics disruptions (port lockdowns, container scarcities, weather events). Multi-country supply routes compound these swings, with price escalation always more severe at the top of the grade spectrum.

Product Price Difference Explanation: Grade, Purity, and Packaging Certification

Grade remains a primary factor: technical and crude grades for veterinary and industrial uses carry lower base pricing, but show more batch-to-batch color and impurity variability. Pharmaceutical and injectable grades demand stringent QC, full trace metals and residual solvent profile, and formal stability data, which steepen production costs. Purity requirements, especially for parenteral grades, drive up both purification and in-process discard rates. Differentiated packaging—sterile, tamper-evident, or multi-compartment systems for regulated markets—adds another cost factor. Where third-party or regulatory inspection of packaging is mandatory, associated costs feed directly into final unit price.

Global Market Analysis & Price Trends

Global Supply & Demand Overview

Global supply is dominated by China and India, where scale and access to essential starting materials enable cost leadership. The US and EU market influence is magnified by regulatory stringency and sustained procurement for institutional healthcare. Price competition remains lowest in highly regulated markets due to high entry barriers. Temporary market imbalances, especially in the wake of site closures in Asia or disrupted logistic chains from global disruptions, routinely drive demand spikes and sector-wide price responses. Veterinary use remains meaningfully lower cost, taking primarily from technical grade channels, but is not immune to ripple effects from API market price moves.

Key Economies Analysis (US/EU/JP/IN/CN)

China: As the largest global producer, Chinese output directly sets the global floor price, yet is acutely vulnerable to local policy actions—particularly environmental and EPC compliance.

India: Significant manufacturing base for both API and finished formulation. Imports high-purity intermediates from China, but is also growing internal capacity. Margins are habitually squeezed by both regulatory cost spikes and rupee volatility.

EU & US: Regulatory certification defines pricing, with greater price stability; significant dependence on approved DMF holders. Delayed regulatory review periods after overseas supply interruptions can cause multi-month procurement spikes.

Japan: Imports much of its API but retains strict documentation and process audit requirements, supporting a premium for full-traceability grade suppliers.

2026 Price Trend Forecast

Assuming regulatory and energy market disruptions continue at recent pace, and no large-scale new entrant expands output dramatically, base pricing for metronidazole is likely to remain firm with periodic volatility. Discounting for off-spec technical grade may deepen during global oversupply, but certified API grades should hold or even rise with ongoing compliance cost growth and GMP audit cycles. External disruptions—geopolitical, port access, raw material embargoes—could cause sudden price surges not recoverable in annual contracts.

Data Sources & Methodology

Commentary draws primarily from internal plant operations logs, procurement market watch reports, and direct customer feedback from formulation buyers in regulated and non-regulated segments. Spot and contract market price surveys, plus regulatory and compliance bulletins, inform the trend and regional impact analysis. Trade flow data supplements production figures for cross-checking capacity claims and real export volumes.

Industry News & Regulatory Updates

Recent Market Developments

Persistent environmental audits in major Asian production zones lead to periodic closures, affecting global supply schedules. This has resulted in longer lead times and a spike in spot-to-contract price gaps during high-demand cycles. Indian manufacturers have upgraded some processing routes to reduce solvent reliance in response to both regulatory and customer audit findings.

Regulatory Compliance Updates

Recent GMP update cycles in both the EU and China reinforce process traceability, particulary for excipient lots and trace solvent residues. US DMF renewal periods have shortened, with new requirements for process change reporting that require closer production documentation alignment at the plant level. Process water and waste handling are both subject to expanded batch-by-batch documentation in export contracts destined for Japan, following recent compliance reviews.

Supplier Response & Mitigation

Manufacturers are investing in process streamlining to insulate against raw material volatility, including booking long-term feedstock contracts and instituting parallel process trains to minimize downtime during audits. Real-time production data monitoring and expanded QC checkpoints, especially with respect to critical impurities and batch consistency, have become standard. Certification upgrades for packaging and shipment tracking are being rolled out for export to sensitive markets, addressing both regulatory inspection readiness and supply chain transparency pressure.

Application Fields & Grade Selection Guide for Metronidazole

Industry Applications

Metronidazole serves multiple sectors, each with distinct functional and regulatory requirements. Pharmaceutical formulations use the highest purity and consistency, often scrutinized batch-to-batch for process yield and trace-level impurities. Veterinary pharmaceutical production applies similar standards, though regional veterinary pharmacopoeia may drive individual acceptance criteria. Industrial applications, such as chemical synthesis intermediates or certain analytical procedures, select technical grade materials based on their reactivity rather than compliance with health authority drug standards. Wastewater treatment sometimes leverages lower grade metronidazole for microbial control, where the critical parameter is active content and cost.

Grade-to-Application Mapping

Grade	Typical Application	Key Parameters
Pharmaceutical Grade	Human APIs, finished drug products	Purity, identified and unidentified impurity content, microbial limits, residual solvent profile
Veterinary Grade	Animal health formulations, veterinary APIs	Purity, impurity pattern, veterinary pharmacopoeia compliance, assay range
Technical/Industrial Grade	Chemical synthesis, non-pharma intermediates, some biocide use	Active content, specific impurity bands, solubility, absence of restricted substances

Key Parameters by Application

Human pharmaceuticals select grades based on ICH Q3A guidelines for organic impurities and strictly monitor residual solvents. Veterinary segments often require fewer residual solvent checks and allow broader limits on specific impurities, depending on jurisdiction. Technical grade batches may tolerate higher impurity levels or mixed crystal habit, especially where downstream synthetic steps neutralize or remove these features. Particle size, thermal stability, and storage moisture are more closely controlled for direct-exposure drug-grade batches. Source of starting materials and approved process route dictate impurity profile—continuous processes tend to tighten batch uniformity against target limits.

How to Select the Right Grade

Step 1: Define Application

Clarity on end-use purpose determines all downstream decisions. Production for registered human pharmaceuticals triggers the need for certified cGMP manufacturing, documentation, and full traceability. Non-pharmaceutical or indirect uses may relax these constraints but still require clarity on application to prevent quality mismatches.

Step 2: Identify Regulatory Requirements

Compliance to current pharmacopoeial monographs (USP, EP, JP, or national standards) and registration dossiers anchors the permitted impurity and test profile for pharmaceutical supply. Veterinary drugs in regulated markets often refer to global pharmacopoeia but may adopt region-specific variations. Technical/industrial users determine acceptability based on contractually agreed in-house specs and statutory chemical control.

Step 3: Evaluate Purity Needs

Required assay, impurity banding (both known and unknown), and residual solvent limits must be matched to downstream sensitivity. Tighten impurity control for highly sensitive dosage forms or when the route of administration increases pharmacological impact. Broader impurity acceptance sometimes suffices in synthesis or biocide contexts, although such choices must not contravene occupational exposure or environmental risk thresholds.

Step 4: Consider Volume & Budget

Production scale, container size, and delivery format directly affect both per-unit pricing and feasibility of custom grade supply. Bulk pharmaceutical and industrial contracts may favor intermediate purity lots for cost savings where end-market requirements allow. High-throughput or large-volume customers should request process-specific, long-term price structures reflecting both quality and scale.

Step 5: Request Sample for Validation

End-user process validation with the actual lot remains the best safeguard. Analytical teams should run comparative method suitability, confirm key impurity markers, and repeat user-specific QC on pilot batches. Production provides technical support to optimize grade in response to actual process performance or regulatory review.

Trust & Compliance: Quality Certifications & Procurement Support for Metronidazole

Quality Compliance & Certifications

Quality Management Certifications

Long-term supply of pharmaceutical and industrial grades of metronidazole comes with attention to site-wide quality frameworks. Our main manufacturing plant operates under a robust quality management system that integrates ICH Q7 principles, ISO 9001-based process controls, and established in-house audit mechanisms. Documentation arising from internal audits and periodic compliance review supports alignment with customer procurement audits, regulatory submissions, and routine inspection processes. Technical management focuses on regular gap analysis between emerging local GMP needs and current plant operations, prioritizing system improvements where necessary.

Product-Specific Certifications

Certificates for metronidazole depend on the specific regulatory and market destination. Depending on the intended application, product shipments include batch-specific Certificates of Analysis (COA) reflecting internal QC release criteria and customer specification alignment. Pharmaceutical-grade lots can be supported by Drug Master Files (DMF) and are assigned relevant registration status with health authorities in qualified regions. Food-grade or veterinary grades are separated during production and follow tailored process validation and documentation protocols. For export, readiness to support CEP, USDMF, and other regulatory dossiers is governed by real-time eligibility for dossier holders and manufacturing country requirements.

Documentation & Reports

Each batch is accompanied by full traceability reports, production records, and in-process monitoring data—supporting each release. Methods for controlling starting material variability, intermediate stability, impurity profile, and residual solvent management are documented across shifts. Raw data snapshots for key parameters—including critical in-process controls, batch reconciliation records, and impurity tracking—are retained according to internal retention schedules and customer specification for audit purposes.

Purchase Cooperation Instructions

Stable Production Capacity Supply and Flexible Business Cooperation Plan

Production scheduling for metronidazole is anchored by high-volume, dedicated synthesis blocks and raw material security agreements. Site logistics teams hold contracted access to critical intermediates and packaging stocks, supporting continuity during routine and peak demand. Downstream users who need periodic ramp-up or call-off schedules can coordinate with our sales support for slot reservations and flexible delivery timelines. For multinational procurement teams, the plant can offer staggered batch release, multi-destination documentation management, and support for synchronized shipping.

Core Production Capacity and Stable Supply Capability

Manufacturing lines are routinely validated for scale transition runs, ensuring that batch consistency does not fluctuate with lot size. Core reactors, filtration systems, and drying units are reserved exclusively for metronidazole series production at any given production window, minimizing cross-contamination risks. Technical staff monitors campaign yield tracking, impurity drift, and batch overlap to head off potential bottlenecks. Capacity forecasts are reviewed by production management, with planned preventive maintenance aligned around committed supply contracts, not just theoretical maximums.

Sample Application Process

For formulation design, new registration projects, or comparison studies, reference lots and stability samples are made available with supporting documentation. Request triggers internal sample preparation under controlled conditions, with triage on grade, market eligibility, and end use. Each released sample ships with identity confirmation, reference COA, and handling instructions tailored to the intended technical evaluation. Regulatory or partner-site sampling may be coordinated with qualified technical representatives for on-site assessment or joint verification.

Detailed Explanation of Flexible Cooperation Mode

Flexible cooperation extends across contract types, from firm volume commitments to rolling purchase programs and technical partnership supply schemes. For R&D-scale pilots, split-batch shipment, staged documentation provision, and interim data packages can be arranged. In major projects, the technical team provides proactive impurity management planning, custom documentation development, and regular scheduling updates. Logistics coordination covers temperature-sensitive shipments, secure transit, and, where required, post-release support for troubleshooting or downstream technical advice.

Market Forecast & Technical Support System for Metronidazole

Research & Development Trends

Current R&D Hotspots

The drive to enhance production efficiency and impurity control sits at the forefront of metronidazole R&D initiatives. Teams focus on optimizing catalytic hydrogenation steps, evaluating raw material variability, and establishing robust crystallization protocols. Analytical development tracks nitroso and chlorinated impurities, ensuring compliance with updated compendial standards. In our facilities, continual upgrades of analytical instrumentation match the rising sensitivity requirements from regulatory agencies, narrowing detection thresholds for genotoxic remnants.

New routes using environmentally friendlier oxidants, solvent recovery loops, and alternative feedstock sources mark another R&D priority. These changes stem from raw material supply chain disruption, cost pressure, and environmental driver mandates.

Emerging Applications

API production continues to dominate, but recent research explores metronidazole’s anti-parasitic spectrum in veterinary health, aquaculture, and niche topical medical devices. Application development units are working with downstream formulators on solubility improvement and taste-masking strategies, focusing on pediatric suspensions and veterinary palatability. The emergence of combination drug projects, seeking synergistic blends, brings new compatibility and stability questions for process chemists.

Technical Challenges & Breakthroughs

Consistent impurity reduction remains the hardest challenge, especially as regulators tighten nitrosamine and related substance limits. Successful scale-up of continuous manufacturing processes has started to replace batch-based plants in some regions, boosting both throughput and real-time analytics. Process control improvements, particularly inline PAT for key intermediates, reduce out-of-spec batches. Waste reduction strategies increasingly rely on solvent recovery, on-site neutralization, or third-party valorization partners, but technical integration into legacy production runs brings operational headaches.

Future Outlook

Market Forecast (3–5 Years)

Market demand for metronidazole tracks shifts in regulatory approvals, patent roll-off for related APIs, and livestock sector trends. Production planning departments observe steady forecasting in core regions; any significant expansion emerges where generics penetration or animal health policy shifts. The sector expects heightened demand for grades with well-defined impurity profiles, putting advanced analytical support under greater pressure. Contract manufacturing requests often specify custom impurity windows or require particular particle size ranges, reflecting a more sophisticated, segmented market.

Technological Evolution

The next period will see further migration to solvent- and energy-efficient routes. Increasing adoption of closed-system transfer for volatile reagents aims to meet stricter operator safety guidelines. Inline Quality by Design elements in both reaction and crystallization provide rapid correction loops for batch endpoints. Advanced process control logic, not just statistical trending, underpins the bid for real-time release testing, with rapid actionable data generated close to the point of manufacture. Sustainability targets increasingly push the adoption of biocatalytic and non-chlorinated synthesis steps.

Sustainability & Green Chemistry

Pressure from downstream customers and regulators has already forced material and energy audits across the process. Our sustainability task force works on lifecycle assessments comparing established and alternative synthetic routes. Implementation of waste-minimizing process modifications, like solvent recycling and reactant substitution, hinges on downstream impurity clearance and risk assessment. Green chemistry adaptations must not compromise batch reproducibility or regulatory acceptance, so cross-functional teams evaluate process change proposals from both production and compliance perspectives.

Technical Support & After-Sales Service

Technical Consultation

Direct access to our process chemists and analytical teams supports problem-solving throughout the product lifecycle. Common consulting requests address impurity profile clarification, formulation troubleshooting, or interpretation of analytical data submitted for batch release. Each production site maintains records correlating process conditions with analytical outcomes, enabling retrospective root cause analysis for customer-specific deviations.

Application Optimization Support

Support routinely covers more than simple specification queries. We collaborate with formulators to troubleshoot dissolution rate issues, select compatible excipients, or resolve organoleptic challenges in specialty dosage forms. Customization—for example, adjusting crystalline form or granulation parameter—typically responds to downstream processing or pharmacopoeial compliance needs. Pilot-scale production samples are available for process validation or formulation development, subject to mutual technical agreement.

After-Sales Commitment

Every shipment includes a batch certificate referencing the relevant analytical tests, tailored by grade and destination country. Technical support extends to post-shipment investigations if a customer’s process flags unexpected results, drawing on retained batch samples and process logs. Complaint investigations and CAPA actions aim for traceable root cause identification, bridging production, QA, and customer technical teams. Ongoing documentation and compliance updates reflect evolving international regulatory requirements.

Metronidazole Manufacturing for Industrial Buyers

We produce Metronidazole at a dedicated facility with process lines designed specifically for pharmaceutical intermediates and active ingredients. Our production team operates reactor suites and filtration systems with tracked batch criteria. This allows us to control physical properties, purity, and moisture consistently across shipments. Every output receives documented in-process checks to meet critical benchmarks for appearance, assay, and trace-level related substances.

Industrial Uses Across Market Sectors

Our Metronidazole reaches industrial formulators who supply finished dosage pharmaceuticals, bulk veterinary products, and export consignment fulfillment partners. Facilities with granulation and blending operations require product that maintains crystalline characteristics through mechanical handling and exposure to facility conditions. Bulk powder and technical buyers use our product in oral, topical, and parenteral manufacturing flows where low-baseline impurity profiles support long-term stability. Veterinary groups and animal health licensors depend on consistent supply for API formulation and re-pack applications.

Consistency and Product Quality Control

Raw input selection and stepwise synthesis trackable from start to finish forms the core of our process. Targeted calibration and NIR analysis validate every batch before packing. In-process analytics track intermediate conversions and capture points of potential deviation. Throughout manufacturing, team leads record mixing and transfer steps on-line for real-time traceability. Dedicated QA personnel test assay, solvent residues, and polymorphic form prior to final lot release. Certificates reflect true observed data from batch runs, not round-off or pooled averages.

Packaging and Bulk Supply Arrangements

We offer fiber drums with tamper-evident inner liners and double barrier bulk bags for export shipping. Special cleanroom sacks serve buyers working in ultra-sensitive blending or repack facilities. Palletizing and shrink-wrapping conform to logistical requirements for both sea and air freight. Logistics teams load verified containers that support full inspection at any point in transit, and continuously update shipping information for buyer transparency. Splits and custom lot sizes support contract requirements for scheduled production intervals.

Support and Technical Service for Professional Buyers

Industrial buyers receive direct technical documentation, manufacturing statements, and analytical data packages for every delivery cycle. Our technical team answers specification requests from quality assurance, regulatory, and laboratory teams. Onboarding support covers product handling, batch traceability, and process adaptation based on buyer site requirements. Regular checks and historical performance summaries enable procurement and R&D teams to forecast usage and plan for regulatory submission cycles.

Value to Manufacturers, Distributors, and Professional Sourcing Teams

Production scale enables secure, repeatable supply for schedule-driven manufacturers and contract production facilities. Distributors benefit from cycle-timed deliveries and pre-cleared documentation for entry into regulated markets. Procurement teams receive packaging flexibility, lot trace documentation, and ongoing technical support that streamlines quality review and compliance submissions. We align raw material inputs and production intervals with volume forecasts and regulatory mandates, minimizing lead time disruptions and supply interruptions.

Industrial FAQ